Case Report

Skin Lesions Associated with Nutritional Management of Maple Syrup Urine Disease

Jaraspong Uaariyapanichkul,1,2 Puthita Saengpanit,2 Ponghatai Damrongphol,3,4 Kanya Suphapeetiporn,3,4 and Sirinuch Chomtho1

1Division of Nutrition, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
2Division of Nutrition, Department of Pediatrics, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok 10330, Thailand
3Center of Excellence for Medical Genetics, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
4Excellence Center for Medical Genetics, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok 10330, Thailand

Correspondence should be addressed to Sirinuch Chomtho; sirinuch.c@chula.ac.th

Received 20 April 2017; Revised 8 September 2017; Accepted 12 September 2017; Published 25 October 2017

Academic Editor: Alireza Firooz

Copyright © 2017 Jaraspong Uaariyapanichkul et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Maple syrup urine disease (MSUD; OMIM# 248600) is an autosomal recessive inborn error of metabolism, which can be managed by specific dietary modifications of branched chain amino acid intake. The incidence of MSUD is approximately 1 in 185,000 worldwide [1]. Although each disorder of inborn errors of metabolism is individually rare, their cumulative incidence is substantial (an incidence of 1 in 2,500–5,000 live births) and has been shown to be upwards of 1 in 800 [2].

We report an infant with MSUD who developed cutaneous lesions as a result of isoleucine deficiency while on dietary management. The skin lesions resolved after addition of isoleucine to the diet with normalization of isoleucine levels. We also report subsequent cutaneous lesions as a result of zinc deficiency during the following episode of treatment.

2. Case Report

A 12-day-old male Indian infant was referred to a tertiary care hospital due to poor milk intake and lethargy. The patient was a full-term neonate with an uncomplicated delivery. Although each disorder of inborn errors of metabolism is individually rare, their cumulative incidence is substantial (an incidence of 1 in 2,500–5,000 live births) and has been shown to be upwards of 1 in 800 [2].

We report an infant with MSUD who developed cutaneous lesions as a result of isoleucine deficiency while on dietary management. The skin lesions resolved after addition of isoleucine to the diet with normalization of isoleucine levels. We also report subsequent cutaneous lesions as a result of zinc deficiency during the following episode of treatment.
without any improvement. Initial biochemical investigations showed ketonuria, no metabolic acidosis, normoglycemia, and a mildly elevated level of ammonia (125 μmol/L). Microbiological examinations were all negative. Upon arrival, the patient had seizure and was intubated.

Further biochemical study with plasma amino acid analysis showed a leucine level of 4163.6 μmol/L (reference values: 42–133.1 μmol/L), isoleucine of 499.8 μmol/L (15.1–74.9 μmol/L), and valine of 784.3 μmol/L (73.6–273.1 μmol/L). Thus, the diagnosis of MSUD (maple syrup urine disease) was made based on clinical and biochemical data.

Whole exome sequencing revealed a novel homozygous missense variant c.196G>A (p.Gly66Arg) in the branched chain keto dehydrogenase E1 subunit beta (BCKDHB) gene. The variant was confirmed by PCR-Sanger sequencing to be homozygous in the patient and heterozygous in both parents (Figure 1).

Initial treatment included intravenous fluid and glucose with the aim to provide adequate energy to reduce catabolism and cessation of protein intake for 48–72 hours, administration of cofactors including thiamine, and adjunct treatment of neurological complications. Specific dietary restriction of branched chain amino acids (BCAAs) by using a branched chain-free amino acid supplement was given at the age of 17 days together with expressed breast milk as a source of natural protein via nasogastric tube.

On day 36, natural protein was stopped as the patient developed hospital-acquired pneumonia and diarrhea which resulted in an elevation of BCAAs. On day 45, multiple discrete erythematous macules and papules appeared on the skin of the forehead, hemorrhagic crusts at both upper and lower lips, as well as well-defined erythematous patches at both cheeks, flexor part of neck, forearms, upper anterior chest wall, and perianal regions which rapidly progressed (Figure 2).

The amino acid profile revealed an isoleucine level of 5.9 μmol/L, leucine of 1166 μmol/L, and valine of 159 μmol/L. The serum zinc level was normal (74 μg/dL). Mycological and microbiological examinations were performed and showed
Case Reports in Dermatological Medicine 3

Case Reports in Dermatological Medicine 3

negative results. A final diagnosis of acrodermatitis dysmetabolica due to isoleucine deficiency was made based on the clinical findings and low isoleucine levels through this period. Expressed breast milk was added to the feeds with isoleucine supplementation of 100 mg/day. The patient had been on continuous venovenous hemofiltration for a 48-hour period to reduce elevated leucine levels. In addition, skin care with emollients was administered. The patient showed a rapid improvement in the skin lesions which started to recover within 2 days and healed in 10 days with no hyperpigmentation. Subsequent amino acid profile showed an increment of isoleucine to a normal level (45.97 μmol/L).

After hospital discharge, the feeding regimens were continued with branched chain-free amino acid supplement and expressed breast milk with supplementation of isoleucine 100 mg/day and valine 50 mg/day to prevent the deficiency, which yielded total energy of 130 kcal/kg/day, total protein of 3 g/kg/day, leucine, isoleucine, and valine of 50 mg/kg/day each.

A subsequent episode of cutaneous manifestations occurred at the age of 6 months. The patient developed severe lethargy. Leucine encephalopathy was initially suspected and dietary management with cessation of natural protein intake was started as a part of the MSUD emergency protocol. Despite receiving seemingly adequate energy (110 kcal/kg/day) and protein intake from branched chain-free amino acid supplement (3 g/kg/day), the patient’s level of consciousness was slow to improve and he was on natural protein exclusion for an extended period despite continuing isoleucine and valine supplementation. A complication of parainfluenza infection and a significant period of diarrhea soon followed and he had been on enteral supplementation of zinc sulfate 2 mg/kg/day together with other micronutrients supplementation. Ten days after admission, disseminated brown maculopapular exanthem appeared on the skin of the extremities, as well as well-defined erythematous patches on the perianal region (Figure 3).

Isoleucine deficiency was initially suspected; however, the amino acid profile later still showed elevated levels of branched chain amino acids with leucine of 533.25 μmol/L (41.63–189.6 μmol/L), isoleucine of 490.53 μmol/L (18.37–72.26 μmol/L), and valine of 400.05 μmol/L (78.57–263.66 μmol/L). Hence, in this subsequent episode of cutaneous manifestation, zinc deficiency causing acrodermatitis enteropathica was confirmed as the serum zinc level was low (56.9 μg/dL) despite continued supplementation.

Skin lesions showed no significant improvement after an increased dosage of enteral chelated zinc to 4 mg/kg/day. Parenteral nutrition with added zinc was then given intravenously due to suspected malabsorption. However, the skin lesions continued to worsen with desquamation in the following week. The patient became edematous, also suspected to be from protein deficiency as a result of malabsorption during the course of treatment (Figure 4). Albumin transfusion, parenteral nutrition containing limited amount of amino acids (based on leucine intake), and extra zinc were given along with branched chain-free amino acid supplement and led to his recovery.

3. Discussion

Dietary restriction of BCAAs (leucine, valine, and isoleucine) while avoiding their deficiency, maintaining growth and nutritional status, and avoiding catabolism is the mainstay of nutritional therapy in MSUD [3]. The aim is to maintain plasma BCAA concentrations within a target treatment range that is not associated with neurotoxicity [3].

The patient developed isoleucine deficiency and presented with skin lesions of acrodermatitis dysmetabolica. These cutaneous lesions have been described during treatment of aminoacidopathies (MSUD) [4, 5] and organic
acidemias (methylmalonic acidemia, glutaric aciduria, and propionic acidemia) [6, 7] due to deficiency of isoleucine. It has been called acrodermatitis acidaemica [6–10] or acrodermatitis dysmetabolica [10, 11]. Other nutritional causes have also been described such as biotin and free fatty acid deficiency [12]. Nevertheless, inadequate intake of BCAAs can also induce exfoliative erythroderma in MSUD infants [13].

In Thailand, MSUD patients have been diagnosed; however, there is no report in details regarding the complication of skin manifestations. Our patient had the clinical profile and responded to treatment similar to the cases with isoleucine deficiency described previously. Treatment options to prevent deficiency of branched chain amino acids include supplementation with specific amino acid powder, supplementation of expressed breast milk, or infant formula with known amino acid concentration as sources of natural protein. It is also necessary to frequently monitor the patients to optimize their growth and dietary intake and ensure normal levels of branched chain amino acids.

During the treatment course, skin lesions can develop. It is essential to be aware of their causes such as zinc deficiency and specific amino acid deficiency despite enteral supplementation. Malabsorption can occur, especially during and after an episode of diarrhea or infection. For this patient, parenteral nutrition is delayed during the turnaround time for laboratory reports of plasma amino acids and zinc which were not readily available in Thailand. We believe that this scenario is still pertinent with other developing countries as well. Nevertheless, we do hope that, by learning from this case, caregivers will become more aware of these complications and may lead to better care for patients with inborn errors of metabolism, especially regarding earlier initiation of parenteral nutrition.

4. Learning Points
(i) Skin lesions in MSUD patients could arise from multiple causes.
(ii) Nutritional deficiency including isoleucine, zinc, and protein deficiency can occur and could complicate the treatment course, even while on enteral supplementation as a result of malabsorption. Parenteral nutrition should be considered and initiated accordingly.
(iii) Clinical status, as well as BCAA levels, should be closely monitored in MSUD patients.

Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication of this paper.

References
[1] L. J. Elsas and P. B. Acosta, "Inherited metabolic disease: Amino acids, Organic acids, and Galactose," in Modern Nutrition in Health and Disease, A. C. Ross, B. Caballo, R. J. Cousins, K. L. Tucker, and T. R. Ziegler, Eds., pp. 906–969, Lippincott Williams & Wilkin, Philadelphia, Pa, USA, 11th edition, 2014.
[2] C. M. Mak, H.-C. H. Lee, A. Y.-W. Chan, and C.-W. Lam, "Inborn errors of metabolism and expanded newborn screening: Review and update," Critical Reviews in Clinical Laboratory Sciences, vol. 50, no. 6, pp. 142–162, 2013.
[3] F. White, "Disorders of amino acid metabolism, organic acidemias and urea cycle defects; Maple syrup urine disease," in Clinical Paediatric Dietetics, V. Shaw and M. Lawson, Eds., pp. 399–403, Blackwell Publishing, Oxford, UK, 4th edition, 2015.
[4] B. Ross, M. Kumar, H. Srinivasan, and A. V. Ekbote, "Isoleucine deficiency in a neonate treated for maple syrup urine disease masquerading as acrodermatitis enteropathica," Indian Pediatrics, vol. 53, no. 8, pp. 738–740, 2016.
[5] I. Templier, J.-L. Reymond, M.-A. Nguyen et al., "Acrodermatitis enteropathica-like syndrome secondary to branched-chain amino acid deficiency during treatment of maple syrup urine disease," Annales de Dermatologie et de Venereologie, vol. 133, no. 4, pp. 375–379, 2006.
[6] S. Niiyama, S. Koelker, I. Degen, G. F. Hoffmann, R. Happle, and R. Hoffmann, "Acrodermatitis acidaemica secondary to malnutrition in glutaric aciduria type I," European Journal of Dermatology, vol. 11, no. 3, pp. 244–246, 2001.
[7] L. De Raeve, L. De Meirleir, J. Ramet, V. Vandenhals, and E. Gerlo, "Acrodermatitis enteropathica-like cutaneous lesions in organic aciduria," Journal of Pediatrics, vol. 124, no. 3, pp. 416–420, 1994.
[8] A. M. Bosch, J. H. Sillevis Smitt, A. H. Van Gennip et al., "Iatrogenic isolated isoleucine deficiency as the cause of an acrodermatitis enteropathica-like syndrome," British Journal of Dermatology, vol. 139, no. 3, pp. 488–491, 1998.
[9] J. J. Domínguez-Cruz, M. Bueno-Delgado, J. Pereyra, J. Bernabeu-Wittel, and J. Conejo-Mir, "Acrodermatitis enteropathica-like skin lesions secondary to isoleucine deficiency," European Journal of Dermatology, vol. 21, no. 1, pp. 115-116, 2011.
[10] D. Tabanlioglu, S. Ersoy-Evans, and A. Karaduman, "Acrodermatitis enteropathica-like eruption in metabolic disorders: Acrodermatitis dysmetabolica is proposed as a better term," Pediatric Dermatology, vol. 26, no. 2, pp. 150–154, 2009.
[11] K. Flores, R. Chikowski, and D. S. Morrell, "Acrodermatitis dysmetabolica in an infant with maple syrup urine disease," Clinical and Experimental Dermatology, vol. 41, no. 6, pp. 651–654, 2016.
[12] K. A. Gehrig and J. G. H. Dinulos, "Acrodermatitis due to nutritional deficiency," Current Opinion in Pediatrics, vol. 22, no. 1, pp. 107–112, 2010.
[13] H. Northrup, E. S. Sigman, and A. A. Hebert, "Exfoliative Erythroderma Resulting From Inadequate Intake of Branched-Chain Amino Acids in Infants With Maple Syrup Urine Disease," JAMA Dermatology, vol. 129, no. 3, pp. 384–385, 1993.